http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103562725-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96486 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-328 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-564 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2012-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103562725-B |
| titleOfInvention | The diagnosis marker of mucocutaneous lymphnode syndrome and therapy target |
| abstract | Present invention provide for diagnosis and the compositions for the treatment of mucocutaneous lymphnode syndrome and method.More specifically, protein group enrichment sleeping protein A, the tenuin B and tenuin C of KD patient, described albumen is used as the biomarker (with potential therapy target) of KD.Therefore, using compositions provided herein and method to detect these biomarkers can be that the therapy being delivered to experimenter provides information. |
| priorityDate | 2011-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 230.